This Project Grant award of $942,442 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the Dana-Farber Cancer Institute (DFCI) to identify the mechanisms driving the rapid evolution of cancer genomes. The key objectives are to understand the processes of chromothripsis, a catastrophic mutational event involving massive chromosome rearrangement, and chromoplexy, another poorly understood mutational process common in cancer. Using...
The Dana-Farber Cancer Institute, Inc. received a $248,819.82 Project Grant award from the National Cancer Institute's Cancer Research Manpower federal grant program (CFDA 93.398) to support research from April 1, 2021 through January 15, 2022. The grant funding will support Dr. Carrot-Zhang's research aiming to understand the landscape of ancestry effects on genomic features of lung adenocarcinoma and elucidate the influence of ancestry on clinical outcomes. Leveraging large sequencing datasets...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $872,555 in funding to the Dana-Farber Cancer Institute (DFCI) to enhance and further develop informatics methods for long-read cancer genome sequencing. The overarching goal is to catalyze long-read cancer genome sequencing efforts through the development of bioinformatic tools for somatic variant discovery from both long-read alignments and de novo...
This federal Project Grant award, valued at $513,859.00 and provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a persistent and continuously renewing adoptive cellular therapy platform using hematopoietic stem cell (HSC)-derived natural killer (NK) cells expressing chimeric antigen receptors (CARs). The key goals are to: (1) leverage naturally occurring NK-specific regulatory elements to drive CAR expression exclusively in NK cells, thereby...
This Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, provided $136,080 under the Cancer Research Manpower federal grant program (CFDA 93.398) to Dana-Farber Cancer Institute from May 3, 2021 through July 15, 2021. The grant supported research aimed at determining the three-dimensional protein structures of phosphatase 2A holoenzyme complexes formed in response to perphenazine and related small molecules, to elucidate the mechanisms by...
This is a $1,593,000 federal Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant was awarded on September 1, 2023 to The Children's Hospital Corporation, doing business as Boston Children's Hospital, a non-profit pediatric teaching hospital and research center. The funding supports a 3-year research project to "DEFINING THE UNIVERSAL GENOMIC LANGUAGE OF HALLMARKS IN TUMOR...
This $720,252 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support a research project led by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to identify genetic variants that confer risk of common cancers, particularly prostate cancer, across diverse ancestral populations. The key products and services to be delivered include: Profiling regulatory element...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
This federal Project Grant award is provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398). The $170,640 grant supports a project titled "The Role of Histone Cleavage in Breast Cancer" at the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts. The research aims to investigate the role of the histone demethylase KDM4C in driving tumor growth in a subset of triple-negative breast cancer (TNBC). The project will leverage...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
This $330,543.28 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, was awarded under the Cancer Research Manpower federal grant program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. for the period of August 16, 2021 through March 31, 2022.
The grant funds research aimed at developing a pan-cancer atlas of driver mutations in over 100,000 patients through a hypothesis-driven combined computational and experimental approach. Specifically, the grant supports efforts to: reveal the biological role of non-coding driver mutations; capture the coordination of multiple driver events at a pathway level; and profile the effects of non-coding drivers on cancer gene expression. The research is designed to enhance understanding of non-coding driver mutations and their combinations to pave the way for new targeted cancer therapies.